July 12, 2013
Septicemia refers to the presence of pathogens in the bloodstream that leads to sepsis, a potentially life-threatening medical condition characterized by whole-body inflammation and the presence of infection. When microbes infect the blood, skin, lungs or other tissues, the body's immune system generates an inflammatory response in an attempt to fight the infection. The body's immune response to the infection causes the characteristic symptoms of sepsis and can lead to organ failure. The current treatment for sepsis requires antibiotics, fluid drainage, blood transfusions, and dialysis. Since individual cases are caused by different microbes, the correct antibiotic must be chosen to treat the infection. This causes a delay in treatment, which leads to an increase in the mortality rate.
Purdue University researchers have developed a novel treatment for septicemia involving molecules derived from chitosan. Chitosan is a linear carbohydrate with many commercial and biomedical uses. This treatment inactivates endotoxins, which are toxins associated with certain types of bacteria and stimulates cytokine release (part of the body's inflammatory response that causes swelling and high fever). This new chitosan shows many advantages over current IV treatments for septicemia. This technology can be used to filter endotoxins out of plasmid DNA samples and filter bacteria from water, making contaminated water samples safe to drink.
由于技术保密工作限制，技术信息无法完全展现，请通过邮箱或短信联系我们，获取更多技术资料。
stimulates cytokine release
plasmid dna samples
body's immune response
current iv treatments
body's inflammatory response
B5, No.1600, North Guoquan Rd, Yangpu, Shanghai
info@yintrust.com
021-65679356
Premium